• +1-646-491-9876
    • +91-20-67278686

    Search

    Integrin Alpha V-Pipeline Review H1 2017

    Integrin Alpha V-Pipeline Review H1 2017

    • Report Code ID: RW0001834446
    • Category Pharmaceuticals
    • No. of Pages 74
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017

    Summary

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 6 and 13 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease and Toxicology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Idiopathic Pulmonary Fibrosis, Diabetic Retinopathy, Fibrosis, Glioblastoma Multiforme (GBM) , Pancreatic Cancer, Cardiovascular Disease, Chemotherapy Effects, Diabetic Macular Edema, Diabetic Nephropathy, Genital Warts (Condylomata Acuminata) , Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) , Kidney Fibrosis, Liver Fibrosis, Malabsorption Syndrome, Melanoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease) and Venous Leg Ulcers (Crural ulcer) .

    The latest report Integrin Alpha V - Pipeline Review, H1 2017, outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
    - The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Overview
    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development
    Biogen Inc
    BioMAS Ltd
    Factor Therapeutics Ltd
    MedImmune LLC
    Merck & Co Inc
    Merck KGaA
    SciFluor Life Sciences LLC
    Vascular Pharmaceuticals Inc
    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drug Profiles
    264-RAD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    abituzumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AC-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AS-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BG-00011 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-16Y - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cilengitide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CWHM-12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-0429 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OCU-200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Proagio - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RSF-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SF-0166 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize Integrin Alpha V and Beta 1 for Cardiovascular Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize Integrin Alpha V for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tetraiodothyroacetic acid - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VF-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VPI-2690B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Dormant Products
    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Discontinued Products
    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Product Development Milestones
    Featured News & Press Releases
    May 08, 2017: Ocugen Expands Global Patent Portfolio for OCU200
    Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update
    Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update
    Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)
    Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
    Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US
    Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board
    Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
    May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find
    May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology
    Apr 02, 2016: Iceni Pharmaceuticals announces appointment of cilengitide inventor Prof. Dr. Horst Kessler to its Scientific Advisory Board
    Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
    Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200
    Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update
    Sep 26, 2014: Merck Serono to Present Data on Abituzumab at the ESMO
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Biogen Inc, H1 2017
    Pipeline by BioMAS Ltd, H1 2017
    Pipeline by Factor Therapeutics Ltd, H1 2017
    Pipeline by MedImmune LLC, H1 2017
    Pipeline by Merck & Co Inc, H1 2017
    Pipeline by Merck KGaA, H1 2017
    Pipeline by SciFluor Life Sciences LLC, H1 2017
    Pipeline by Vascular Pharmaceuticals Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017
    Dormant Products, H1 2017 (Contd..3) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Biogen Inc
    BioMAS Ltd
    Factor Therapeutics Ltd
    MedImmune LLC
    Merck & Co Inc
    Merck KGaA
    SciFluor Life Sciences LLC
    Vascular Pharmaceuticals Inc

    Request for Sample

    Report Url https://www.reportsweb.com//integrin-alpha-v-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//integrin-alpha-v-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//integrin-alpha-v-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments